Prospective randomized trials testing the efficacy of gilteritinib maintenance, following consolidation (NCT02927262), and after alloHSCT (NCT02997202) (Table 1) remain critical to determine the ultimate role of FLT3 TKIs in maintenance therapies and the necessary treatment duration for FLT3-mutant AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.